Inhixa 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0106 
A.7 - Administrative change - Deletion of 
12/12/2023 
Annex II and 
manufacturing sites 
PL 
IA/0104/G 
This was an application for a group of variations. 
28/11/2023 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0102/G 
This was an application for a group of variations. 
15/11/2023 
n/a 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
IB/0100 
B.I.a.1.z - Change in the manufacturer of AS or of a 
30/08/2023 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
N/0099 
Minor change in labelling or package leaflet not 
24/07/2023 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0098 
B.II.e.5.a.1 - Change in pack size of the finished 
07/07/2023 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
SmPC, 
Labelling and 
PL 
IB/0097 
B.I.b.2.e - Change in test procedure for AS or 
07/07/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
Page 2/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0095/G 
This was an application for a group of variations. 
05/05/2023 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
IAIN/0096 
B.II.b.2.c.1 - Change to importer, batch release 
01/03/2023 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Annex II and 
PL 
IA/0094/G 
This was an application for a group of variations. 
06/02/2023 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0093/G 
This was an application for a group of variations. 
21/12/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
Page 3/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0092 
B.II.e.1.z - Change in immediate packaging of the 
03/11/2022 
n/a 
finished product - Other variation 
IB/0091/G 
This was an application for a group of variations. 
02/11/2022 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0089/G 
This was an application for a group of variations. 
25/05/2022 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IB/0090 
B.II.b.3.z - Change in the manufacturing process of 
05/05/2022 
n/a 
the finished or intermediate product - Other variation 
IB/0087 
B.I.a.1.z - Change in the manufacturer of AS or of a 
01/03/2022 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0088 
B.II.b.3.a - Change in the manufacturing process of 
21/02/2022 
n/a 
the finished or intermediate product - Minor change 
Page 4/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in the manufacturing process 
PSUSA/10833
Periodic Safety Update EU Single assessment - 
11/11/2021 
06/01/2022 
SmPC, 
Refer to Scientific conclusions and grounds recommending 
/202104 
enoxaparin 
Labelling and 
the variation to terms of the Marketing Authorisation(s)’ for 
PL 
PSUSA/10833/202104. 
IB/0086 
B.II.e.7.b - Change in supplier of packaging 
04/01/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IAIN/0085/G 
This was an application for a group of variations. 
15/12/2021 
16/12/2022 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 5/35 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 6/35 
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 7/35 
 
 
 
 
 
IB/0084 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/12/2021 
20/01/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0083/G 
This was an application for a group of variations. 
23/11/2021 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0082 
C.I.11.z - Introduction of, or change(s) to, the 
03/11/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
R/0076 
Renewal of the marketing authorisation. 
24/06/2021 
26/08/2021 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of Inhixa 
PL 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IAIN/0081 
B.II.b.1.a - Replacement or addition of a 
30/06/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0079 
B.II.b.1.a - Replacement or addition of a 
22/04/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
Page 8/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
IAIN/0078 
A.5.a - Administrative change - Change in the name 
13/04/2021 
27/05/2021 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
IAIN/0077 
B.II.b.2.c.1 - Change to importer, batch release 
17/02/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0073/G 
This was an application for a group of variations. 
04/02/2021 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
IA/0075 
B.II.b.5.b - Change to in-process tests or limits 
07/01/2021 
n/a 
applied during the manufacture of the finished 
Page 9/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Addition of a new test(s) and limits 
IAIN/0074/G 
This was an application for a group of variations. 
21/12/2020 
27/05/2021 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 10/35 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
IB/0072 
B.I.b.2.e - Change in test procedure for AS or 
03/12/2020 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0071 
A.5.b - Administrative change - Change in the name 
26/11/2020 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0070/G 
This was an application for a group of variations. 
18/11/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 11/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
PSUSA/10833
Periodic Safety Update EU Single assessment - 
29/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202004 
enoxaparin 
IB/0065/G 
This was an application for a group of variations. 
01/07/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
II/0064 
B.I.a.1.e - Change in the manufacturer of AS or of a 
25/06/2020 
27/05/2021 
Annex II 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
IAIN/0068 
B.II.b.2.c.1 - Change to importer, batch release 
17/06/2020 
n/a 
Page 12/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0067 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
26/05/2020 
27/05/2021 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0066/G 
This was an application for a group of variations. 
06/05/2020 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
N/0062 
Minor change in labelling or package leaflet not 
19/03/2020 
27/05/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0063 
B.II.b.3.a - Change in the manufacturing process of 
11/03/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 13/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0061/G 
This was an application for a group of variations. 
27/02/2020 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0058 
Transfer of Marketing Authorisation 
17/01/2020 
10/02/2020 
SmPC, 
Labelling and 
PL 
IB/0059/G 
This was an application for a group of variations. 
03/02/2020 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
Page 14/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the AS - Other 
variation 
B.II.d.1.h - Change in the specification parameters 
and/or limits of the finished product - Update of the 
dossier to comply with the provisions of an updated 
general monograph of the Ph. Eur. for the finished 
product 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
IA/0060/G 
This was an application for a group of variations. 
31/01/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0057 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
19/12/2019 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0056/G 
This was an application for a group of variations. 
29/11/2019 
10/02/2020 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 15/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IA/0055 
B.II.d.2.a - Change in test procedure for the finished 
07/11/2019 
n/a 
product - Minor changes to an approved test 
procedure 
PSUSA/10553
Periodic Safety Update EU Single assessment - 
31/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201904 
enoxaparin (biosimilars) 
N/0054 
Minor change in labelling or package leaflet not 
24/10/2019 
10/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0053 
B.II.e.7.b - Change in supplier of packaging 
11/09/2019 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IB/0052 
B.II.e.7.b - Change in supplier of packaging 
02/09/2019 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
II/0048/G 
This was an application for a group of variations. 
25/07/2019 
29/10/2019 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
Labelling and 
PL 
Page 16/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological/immunological medicinal products 
IB/0047/G 
This was an application for a group of variations. 
02/07/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
N/0049 
Minor change in labelling or package leaflet not 
12/06/2019 
29/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0045 
B.II.b.4.a - Change in the batch size (including batch 
30/05/2019 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
PSUSA/10553
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
/201810 
enoxaparin (biosimilars) 
IB/0046 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
14/03/2019 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 17/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0042 
B.II.b.4.a - Change in the batch size (including batch 
25/02/2019 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IA/0044 
A.7 - Administrative change - Deletion of 
04/01/2019 
n/a 
manufacturing sites 
N/0041 
Minor change in labelling or package leaflet not 
17/12/2018 
29/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0040/G 
This was an application for a group of variations. 
07/12/2018 
29/10/2019 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 18/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
PSUSA/10553
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201804 
enoxaparin (biosimilars) 
IB/0039/G 
This was an application for a group of variations. 
06/11/2018 
29/10/2019 
SmPC, Annex 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
II, Labelling 
and PL 
IA/0038 
A.7 - Administrative change - Deletion of 
31/10/2018 
n/a 
manufacturing sites 
N/0037 
Minor change in labelling or package leaflet not 
10/10/2018 
29/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
X/0026 
Annex I_2.(c) Change or addition of a new 
26/07/2018 
17/09/2018 
SmPC, 
strength/potency 
Labelling and 
PL 
Page 19/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X/0018 
Annex I_2.(c) Change or addition of a new 
26/07/2018 
17/09/2018 
SmPC, 
strength/potency 
Labelling and 
PL 
IB/0036/G 
This was an application for a group of variations. 
24/08/2018 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0034 
A.7 - Administrative change - Deletion of 
22/06/2018 
17/09/2018 
Annex II and 
manufacturing sites 
PL 
II/0031 
B.II.b.2.b - Change to importer, batch release 
07/06/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
Page 20/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0033 
Minor change in labelling or package leaflet not 
07/05/2018 
17/09/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0032 
Minor change in labelling or package leaflet not 
11/04/2018 
17/09/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0030/G 
This was an application for a group of variations. 
27/03/2018 
17/09/2018 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 21/35 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0029/G 
This was an application for a group of variations. 
02/03/2018 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
N/0028 
Minor change in labelling or package leaflet not 
31/01/2018 
17/09/2018 
PL 
Page 22/35 
 
 
 
 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
IB/0025/G 
This was an application for a group of variations. 
10/01/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
IAIN/0027 
B.II.b.1.a - Replacement or addition of a 
18/12/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0024/G 
This was an application for a group of variations. 
30/11/2017 
17/09/2018 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
Page 23/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0022 
B.II.e.3.z - Change in test procedure for the 
24/11/2017 
n/a 
immediate packaging of the finished product - Other 
variation 
IB/0021 
B.I.b.2.c - Change in test procedure for AS or 
31/10/2017 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
IAIN/0023/G 
This was an application for a group of variations. 
27/10/2017 
17/09/2018 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Labelling and 
PL 
Page 24/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 25/35 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 26/35 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
N/0020 
Minor change in labelling or package leaflet not 
04/10/2017 
17/09/2018 
PL 
Page 27/35 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10553
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201703 
enoxaparin (biosimilars) 
IA/0017 
B.II.d.2.a - Change in test procedure for the finished 
26/07/2017 
n/a 
product - Minor changes to an approved test 
procedure 
N/0016 
Minor change in labelling or package leaflet not 
20/06/2017 
17/07/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0014/G 
This was an application for a group of variations. 
08/06/2017 
17/07/2017 
SmPC, Annex 
II, Labelling 
and PL 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
C.I.1.b - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a Union 
referral procedure - The product is not covered by 
the defined scope of the procedure but the change(s) 
implements the outcome of the procedure and no 
new additional data is required to be submitted by 
the MAH 
IAIN/0013/G 
This was an application for a group of variations. 
19/05/2017 
17/07/2017 
SmPC, Annex 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
II, Labelling 
and PL 
Page 28/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 29/35 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
II/0009/G 
This was an application for a group of variations. 
21/04/2017 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
Page 30/35 
 
 
 
 
 
 
 
 
 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.c.1.z - Change in immediate packaging of the AS 
- Other variation 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0012/G 
This was an application for a group of variations. 
20/04/2017 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
Page 31/35 
 
 
 
 
 
 
 
 
 
changes to an approved test procedure 
IB/0011/G 
This was an application for a group of variations. 
30/03/2017 
17/07/2017 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
II/0005/G 
This was an application for a group of variations. 
30/03/2017 
n/a 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
IB/0008/G 
This was an application for a group of variations. 
21/03/2017 
17/07/2017 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
Labelling and 
PL 
Page 32/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 33/35 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.z - Change in pack size of the finished 
product - Other variation 
II/0004/G 
This was an application for a group of variations. 
02/03/2017 
n/a 
B.II.b.1.d - Replacement or addition of a 
manufacturing site for the FP - Site which requires an 
initial or product specific inspection 
B.II.b.5.e - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Widening of the approved IPC limits, which 
may have a significant effect on overall quality of the 
finished product 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0007 
B.II.d.1.d - Change in the specification parameters 
17/01/2017 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
IB/0006 
B.II.d.1.d - Change in the specification parameters 
17/01/2017 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
IB/0003/G 
This was an application for a group of variations. 
22/12/2016 
n/a 
B.II.b.1.z - Replacement or addition of a 
Page 34/35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Other variation 
B.II.e.3.a - Change in test procedure for the 
immediate packaging of the finished product - Minor 
changes to an approved test procedure 
IB/0001 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
16/12/2016 
17/07/2017 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
Page 35/35 
 
 
 
 
 
 
 
 
 
